Vitamin D and Endometrial Receptivity in Infertile Women

The University of Hong Kong (HKU)

Status: Enrolling

Conditions: Infertility

Treatments: Dietary Supplement: Vitamin D

Study type: Observational

Funder types: Other

Identifiers

NCT04721899

UW19-134

Details and patient eligibility

About

This is a prospective study comparing vaginal and endometrial biomarkers and the trophoblast spheroid attachment rate in women with fertility problems before and after taking Vitamin D for 8 weeks.

Full description

The aim of this study is to assess the effect of vitamin D supplementation on vaginal / endometrial biomarkers and endometrial receptivity in women with fertility problems.

Women will have vaginal swab and endometrial biopsy twice. The first endometrial biopsy is performed using a Pipelle sampler 7 days after luteinizing hormone surge (LH+7) at baseline and the attachment rate of the trophoblast spheroid onto the isolated endometrial epithelial cells will be assessed to assess endometrial receptivity at baseline. Implantation biomarkers will be checked.

They will take Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks. After 8 weeks of Vitamin D, a second vaginal swab and endometrial biopsy using a Pipelle sampler by standard technique will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.

The laboratory staff will not know whether the patient is taking any vitamin D when performing the trophoblast spheroid attachment assay/ biomarkers.

Enrollment: 105 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age of women < 40years old
• Normal uterine cavity as demonstrated by pelvic scanning with or without saline infusion sonogram or hysteroscopy
• Regular ovulatory cycles

They will be divided into three groups:

• RIF patients (n=35)- those who have failed to get pregnant after replacing four or more cleavage stage embryos or two or more blastocysts in two consecutive transfers.
• RPL patients (n=35)- those who have failed in three pregnancies before 24 weeks of gestation and includes embryonic and fetal losses.
• 'Infertile group'(n=35)- infertility except RIF and RPL, e.g. those seeking for preimplantation genetic testing, male factor infertility, unexplained infertility.

Exclusion criteria

• History of any medical condition or medications that may predispose to vitamin D sensitivity, altered vitamin D metabolism and/ or hypercalcemia, including active tuberculosis or current therapy for tuberculosis, sarcoidosis, history of renal/ ureteral stones, parathyroid disease, renal or liver failure or current use of anti-convulsants

• Taking vitamin D supplement

• Endometrial polyp or fibroid distorting the uterine cavity

• Presence of hydrosalpinx not corrected surgically

• Refusal to join the study

  • Discontinuation criteria-

• If the woman becomes pregnant during the study

• Pelvic inflammatory disease/ uterine perforation after endometrial biopsy

• Vitamin D toxicity (hypercalcemia)

• Withdrawal by patient

Trial design

105 participants in 3 patient groups

Vitamin D- recurrent implantation failure (RIF)

Description:

All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.

Treatment:

Dietary Supplement: Vitamin D

Vitamin D- recurrent pregnancy loss (RPL)

Description:

All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.

Treatment:

Dietary Supplement: Vitamin D

Vitamin D- infertility

Description:

All women will have endometrial biopsy twice- at baseline and after 8 weeks of taking vitamin D After 8 weeks of Vitamin D, a second endometrial biopsy using a Pipelle sampler will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared.

Treatment:

Dietary Supplement: Vitamin D